ALCL
MCID: ANP001
MIFTS: 60

Anaplastic Large Cell Lymphoma (ALCL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Anaplastic Large Cell Lymphoma:

Name: Anaplastic Large Cell Lymphoma 39 12 54 60 56 15 17
Anaplastic Large-Cell Lymphoma 38 30
Alcl 54 60
Cd30 Positive Anaplastic Large Cell Lymphoma 60
Ki-1 Positive Anaplastic Large Cell Lymphoma 60
Ki-1+ Anaplastic Large Cell Lymphoma 74
Primary Systemic Alcl 60
Sacl 60

Characteristics:

Orphanet epidemiological data:

60
anaplastic large cell lymphoma
Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050744
KEGG 38 H01601
MESH via Orphanet 46 D017728
ICD10 via Orphanet 35 C84.6 C84.7
UMLS via Orphanet 75 C0206180
Orphanet 60 ORPHA98841
UMLS 74 C0206180

Summaries for Anaplastic Large Cell Lymphoma

NIH Rare Diseases : 54 Anaplastic large cell lymphoma (ALCL) is a rare type of Non-Hodgkins lymphoma. Lymphoma is a cancer of the lymph system, part of our immune system. Non-Hodgkins lymphoma involves abnormal growth of white blood cells, either T cells or B cells. Anaplastic large cell lymphoma is an aggressive cancer that usually involves the T-cells. Cancer cells in ALCL can be identified by their appearance under the microscope and by the presence of a tumor marker called CD30 or Ki-1. There are two types of ALCL, a type that affects mainly the skin (cutaneous ALCL) and a type that affects other body organs (systmic ALCL). Systemic ALCL also has two types, ALK-positive (anaplastic lymphoma kinase) and ALK-negative. ALK-positive ALCL occurs more often in children and young adults. ALK-negative ALCL tends to occur in older adults. The symptoms of cutaneous ALCL include red skin lesions that break open and do not heal. Sometimes cutaneous ALCL is also found in the lymph nodes. The symptoms of systemic ALCL include fever, night sweats, and weight loss (B symptoms). The cancer can be found in the bone, soft tissue, spleen, liver and skin. The cause of ALCL is unknown. One type of ALK-negative ALCL has been associated with breast implants.  ALCL is diagnosed by a biopsy of the tumor or abnormal skin and examination of the tumor cells under a microscope. Additional testing including PET scans, CT scans, MRI and a bone marrow biopsy can tell doctors if the cancer has spread to other organs.[15060  ALCL is treated using chemotherapy, and a stem-cell transplant for people with more aggressive cancer or for ALCL that has come back. In addition, there are newer treatments that target the cancer cells directly and have been very effective. In general, ALK-positive ALCL has a better long-term outlook than ALK-negative ALCL.

MalaCards based summary : Anaplastic Large Cell Lymphoma, also known as anaplastic large-cell lymphoma, is related to alk-positive anaplastic large cell lymphoma and primary cutaneous anaplastic large cell lymphoma. An important gene associated with Anaplastic Large Cell Lymphoma is LINC01013 (Long Intergenic Non-Protein Coding RNA 1013), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vincristine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A non-Hodgkin lymphoma involving aberrant T-cells.

Wikipedia : 77 Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma involving aberrant T cells or... more...

Related Diseases for Anaplastic Large Cell Lymphoma

Diseases in the Anaplastic Large Cell Lymphoma family:

Anaplastic Small Cell Lymphoma

Diseases related to Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 33.9 ALK JAK3 MCL1 MUC1 NPM1 STAT3
2 primary cutaneous anaplastic large cell lymphoma 33.8 ALK GZMB MUC1 NPM1 PTPRC
3 lymphoma 32.4 ALK NPM1 PAX5 TNFRSF8
4 reticulosarcoma 31.4 ALK CLU GZMB MUC1 NPM1 PAX5
5 lymphomatoid papulosis 31.4 ALK GZMB NPM1
6 peripheral t-cell lymphoma 30.9 ALK GZMB TNFRSF8
7 lymphoma, hodgkin, classic 30.8 ALK PAX5 PTPRC TNFSF8
8 inflammatory myofibroblastic tumor 30.8 ALK NPM1 RNF213
9 histiocytosis 30.7 CSF1R PTPRC TNFRSF8
10 mycosis fungoides 30.6 CLU GZMB STAT3 TNFRSF8
11 composite lymphoma 30.0 GZMB PAX5
12 mantle cell lymphoma 29.9 MCL1 PAX5 PTPRC STAT3
13 leukemia, acute myeloid 29.7 CSF1R MCL1 NPM1 PTPRC STAT3
14 leukemia, chronic lymphocytic 29.7 MCL1 PAX5 STAT3 TNFSF8
15 sarcoidosis 1 29.4 ALK IL9 PTPRC TNFRSF8 TNFSF8
16 lymphoma, non-hodgkin, familial 27.8 ALK GZMB IL9 MCL1 NPM1 PAX5
17 alk-negative anaplastic large cell lymphoma 12.8
18 anaplastic small cell lymphoma 11.8
19 leukemia 10.5
20 b-cell lymphomas 10.5
21 autoimmune lymphoproliferative syndrome, type v 10.4
22 hemophagocytic lymphohistiocytosis 10.3
23 adult t-cell leukemia 10.3
24 sarcoma 10.3
25 t-cell leukemia 10.3
26 eccrine porocarcinoma 10.3 MUC1 STAT3
27 diffuse large b-cell lymphoma 10.3
28 dermatitis 10.3
29 conventional fibrosarcoma 10.2 PTPRC TNFRSF8
30 colon lymphoma 10.2 ALK PTPRC TNFRSF8
31 breast cancer 10.2
32 human herpesvirus 8 10.2
33 arthritis 10.2
34 lymphocytic leukemia 10.2
35 squamous cell carcinoma 10.2
36 acquired immunodeficiency syndrome 10.2
37 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.2
38 tenosynovial giant cell tumor 10.2 CLU CSF1R
39 reticulum cell sarcoma 10.2 MUC1 PTPRC TNFRSF8
40 malignant leydig cell tumor 10.1 PAX5 TNFRSF8
41 panniculitis 10.1
42 ichthyosis 10.1
43 adenocarcinoma 10.1
44 myeloid leukemia 10.1
45 hypereosinophilic syndrome 10.1
46 soft tissue sarcoma 10.1
47 lymphatic system cancer 10.1 ALK NPM1 PTPRC TNFRSF8
48 myeloid sarcoma 10.1 NPM1 PAX5 PTPRC
49 testicular infarct 10.1 PTPRC TNFRSF8
50 leukemia, chronic lymphocytic 2 10.1

Graphical network of the top 20 diseases related to Anaplastic Large Cell Lymphoma:



Diseases related to Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CLU GZMB JUNB MCL1 TNFSF8 TRAF1

MGI Mouse Phenotypes related to Anaplastic Large Cell Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.9 CSF1R IL9 JAK3 JUNB MCL1 NPM1
2 endocrine/exocrine gland MP:0005379 9.86 ALK CSF1R JAK3 MCL1 PTPRC RNF213
3 immune system MP:0005387 9.77 CLU CSF1R IL9 JAK3 JUNB MCL1
4 neoplasm MP:0002006 9.1 ALK JUNB NPM1 PAX5 PTPRC STAT3

Drugs & Therapeutics for Anaplastic Large Cell Lymphoma

Drugs for Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2068-78-2, 57-22-7 5978
2
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
7
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
8
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
11
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
12
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
13
rituximab Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
14
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
15
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
16
Vindesine Approved, Investigational Phase 4,Not Applicable 59917-39-4, 53643-48-4 40839
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
18
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
20
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
21
Crizotinib Approved Phase 4,Phase 1,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
22
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 51-75-2 4033
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
24
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 31703
25
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
26
Pirarubicin Investigational Phase 4 72496-41-4
27
Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 0
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Folate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
3 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Recruiting NCT01909934 Phase 4 brentuximab vedotin
4 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
5 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
6 A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Withdrawn NCT02487316 Phase 4 crizotinib
7 Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma Unknown status NCT00006455 Phase 3 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;methotrexate;therapeutic hydrocortisone;vinblastine sulfate
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
10 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
11 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
12 Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma Completed NCT00059839 Phase 3 doxorubicin hydrochloride;mercaptopurine;methotrexate;prednisone;vinblastine sulfate;vincristine sulfate
13 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed NCT01578499 Phase 3 Brentuximab Vedotin;Methotrexate;Bexarotene
14 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Completed NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
15 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
18 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
19 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
20 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
22 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
25 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
26 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
27 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
28 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
29 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
30 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
31 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
32 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
33 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
34 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Active, not recruiting NCT01777152 Phase 3 brentuximab vedotin;doxorubicin;prednisone;vincristine;cyclophosphamide
35 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
36 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
37 CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) Unknown status NCT02274584 Phase 1, Phase 2
38 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
39 Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse Unknown status NCT00069966 Phase 2 cisplatin;cytarabine;methylprednisolone;pixantrone dimaleate
40 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
41 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
42 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
43 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
44 Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma Completed NCT00079755 Phase 2 SGN-30 (anti-CD30 mAb)
45 Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed NCT00939770 Phase 1, Phase 2 Crizotinib
46 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma Completed NCT00117988 Phase 2 tanespimycin
47 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed NCT01492088 Phase 1, Phase 2 Brentuximab vedotin
48 Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma Completed NCT00099255 Phase 2 SGN-30
49 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed NCT00866047 Phase 2 brentuximab vedotin
50 Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Completed NCT02280785 Phase 2 Brentuximab vedotin

Search NIH Clinical Center for Anaplastic Large Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Anaplastic Large Cell Lymphoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Anaplastic Large Cell Lymphoma:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Anaplastic Large Cell Lymphoma:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Anaplastic Large Cell Lymphoma

Genetic tests related to Anaplastic Large Cell Lymphoma:

# Genetic test Affiliating Genes
1 Anaplastic Large-Cell Lymphoma 30

Anatomical Context for Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Anaplastic Large Cell Lymphoma:

42
T Cells, Breast, Bone, Bone Marrow, B Cells, Skin, Liver

Publications for Anaplastic Large Cell Lymphoma

Articles related to Anaplastic Large Cell Lymphoma:

(show top 50) (show all 1582)
# Title Authors Year
1
CD38 is not expressed in pediatric ALK-positive anaplastic large cell lymphoma. ( 30408331 )
2019
2
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. ( 30562196 )
2019
3
Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death. ( 30679328 )
2019
4
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. ( 30685783 )
2019
5
Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. ( 30742941 )
2019
6
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. ( 30873584 )
2019
7
Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. ( 30521149 )
2019
8
Complexity of health news reporting on breast implant-associated anaplastic large cell lymphoma. ( 30592350 )
2019
9
Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management. ( 30596216 )
2019
10
A practical cytological approach to the diagnosis of breast-implant associated anaplastic large cell lymphoma. ( 30628128 )
2019
11
Outcome and prognosis of anaplastic large cell lymphoma in children: a report from the Taiwan Pediatric Oncology Group. ( 30646784 )
2019
12
Acitretin Combined with NB-UVB in the Treatment of Cutaneous CD30-positive Anaplastic Large Cell Lymphoma. ( 30659723 )
2019
13
EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. ( 30703669 )
2019
14
Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715169 )
2019
15
Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective. ( 30715171 )
2019
16
The Cellular Origins of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Implications for Immunogenesis. ( 30715172 )
2019
17
2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715173 )
2019
18
What Cytokines Can Tell Us About the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). ( 30715174 )
2019
19
Introduction to the "Current Controversies in Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)" Supplement. ( 30715175 )
2019
20
Anaplastic large cell lymphoma with TP63 rearrangement: A dismal prognosis. ( 30719810 )
2019
21
Cutaneous Abscess: An Isolated Manifestation of Disseminated Anaplastic Large-cell Lymphoma in a Child. ( 30745646 )
2019
22
The First Reported Case of Gluteal Implant-Associated Anaplastic Large Cell Lymphoma (ALCL). ( 30768141 )
2019
23
Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30789639 )
2019
24
Commentary on: Validation of a CD30 Enzyme-Linked Immunosorbant Assay for the Rapid Detection of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30789658 )
2019
25
Lethal cardiac damage resulting from eosinophilia caused by anaplastic large cell lymphoma. ( 30793295 )
2019
26
Validation of CD137 Immunohistochemical Stain on Paraffin-Embedded Tissue as a Marker to Facilitate Distinction Between Classic Hodgkin Lymphoma, Nodular Lymphocyte-Predominant Hodgkin Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, and Anaplastic Large Cell Lymphoma. ( 30816829 )
2019
27
"A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma": The Supplement. ( 30817548 )
2019
28
Financial Disclosure Appendix for "A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma". ( 30817549 )
2019
29
Introduction to "A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma". ( 30817550 )
2019
30
Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. ( 30817551 )
2019
31
Achieving Reliable Diagnosis in Late Breast Implant Seromas: From Reactive to Anaplastic Large Cell Lymphoma. ( 30817552 )
2019
32
Theories of Etiopathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30817553 )
2019
33
Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. ( 30817554 )
2019
34
Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30817555 )
2019
35
Breast Reconstruction Following Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30817556 )
2019
36
Molecular Drivers of Breast Implant-Associated Anaplastic Large Cell Lymphoma. ( 30817557 )
2019
37
Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012-2018. ( 30817558 )
2019
38
Leukemic presentation of ALK+ Anaplastic Large Cell Lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. ( 30819904 )
2019
39
A Case of Congenital Anaplastic Large Cell Lymphoma in a Very Preterm Low-Birth Weight Neonate. ( 30830032 )
2019
40
Composite breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and extra-nodal marginal zone lymphoma (MZL) in the capsule of a silicone breast implant. ( 30844557 )
2019
41
Clinical Features and Treatment Outcomes of Children With Anaplastic Large Cell Lymphoma in Pakistan: A Multicenter Study. ( 30855316 )
2019
42
How Breast Implant Surface Type Is Influenced by Breast Implant-associated Anaplastic Large Cell Lymphoma: A Survey of the American Society of Plastic Surgeons. ( 30855390 )
2019
43
The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis. ( 30878517 )
2019
44
A first time report on the coocurrence of sarcoidosis and ALK(-) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment. ( 30909793 )
2019
45
Response to "Determining the True Incidence of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Need for Accurate Data". ( 30915437 )
2019
46
Determining the True Incidence of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Need for Accurate Data. ( 30916317 )
2019
47
A Different Perspective on Breast Implant Surface Texturization and Anaplastic Large Cell Lymphoma (ALCL). ( 29659699 )
2019
48
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. ( 29302678 )
2018
49
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
50
Improvement of cutaneous anaplastic large cell lymphoma by brentuximab vedotin monotherapy. ( 29391331 )
2018

Variations for Anaplastic Large Cell Lymphoma

Cosmic variations for Anaplastic Large Cell Lymphoma:

9 (show all 40)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM45929 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.408A>C p.Q136H 17:7675204-7675204 0
2 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
3 COSM43989 TP53 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.596G>A p.G199E 17:7674935-7674935 0
4 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 0
5 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 0
6 COSM10813 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.394A>G p.K132E 17:7675218-7675218 0
7 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 0
8 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 0
9 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 0
10 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 0
11 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 0
12 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 0
13 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 0
14 COSM1155739 STAT3 haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.1981G>T p.D661Y 17:42322402-42322402 0
15 COSM1155745 STAT3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.1981G>C p.D661H 17:42322402-42322402 0
16 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 0
17 COSM6987010 SPEN haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.92G>A p.R31H 1:15872824-15872824 0
18 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 0
19 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 0
20 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 0
21 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 0
22 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 0
23 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 0
24 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 0
25 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 0
26 COSM580 NRAS haematopoietic and lymphoid tissue,skin,lymphoid neoplasm,anaplastic large cell lymphoma c.181C>A p.Q61K 1:114713909-114713909 0
27 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 0
28 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 0
29 COSM6987011 CCND1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.505C>G p.P169A 11:69643922-69643922 0
30 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 0
31 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
32 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
33 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
34 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 0
35 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 0
36 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 0
37 COSM6987012 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,anaplastic large cell lymphoma c.505C>G p.P169A 11:69643922-69643922 0
38 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 0
39 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 0
40 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 0

Copy number variations for Anaplastic Large Cell Lymphoma from CNVD:

7 (show all 11)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 19994 1 152394403 152431233 Translate TPM3 Anaplastic large cell lymphoma
2 122442 18 56200000 78077248 Loss Anaplastic large cell lymphoma
3 154895 20 49800000 58400000 Gain Anaplastic large cell lymphoma
4 154985 20 5100000 42100000 Gain Anaplastic large cell lymphoma
5 166394 3 101910849 101950501 Translate TFG Anaplastic large cell lymphoma
6 199890 5 4500000 23300000 Gain Anaplastic large cell lymphoma
7 264349 X 64804235 64878518 Translate MSN Anaplastic large cell lymphoma
8 300361 11 128069198 128187521 Translocation FLI1 Anaplastic large cell lymphoma
9 303153 2 29269143 29997936 Translocation ALK Anaplastic large cell lymphoma
10 303499 22 27994016 28026515 Translocation EWSR1 Anaplastic large cell lymphoma
11 304007 5 170747402 170770493 Translocation NPM1 Anaplastic large cell lymphoma

Expression for Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Anaplastic Large Cell Lymphoma.

Pathways for Anaplastic Large Cell Lymphoma

Pathways related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CLU CSF1R IL9 JAK3 JUNB MCL1
2
Show member pathways
13.67 ALK CSF1R IL9 JAK3 JUNB MUC1
3
Show member pathways
13.21 ALK CSF1R IL9 JAK3 JUNB STAT3
4
Show member pathways
13.08 CSF1R IL9 JAK3 JUNB MCL1 MUC1
5 12.57 ALK CSF1R JAK3 STAT3 TFG TRAF1
6 12.09 CSF1R GZMB PAX5 TRAF1
7
Show member pathways
12 CSF1R IL9 JAK3 MCL1 PTPRC STAT3
8
Show member pathways
11.85 JAK3 JUNB STAT3
9 11.74 GZMB JAK3 JUNB PAX5 PTPRC STAT3
10 11.65 CSF1R JAK3 PTPRC STAT3
11 11.62 GZMB IL9 PTPRC
12 11.41 JAK3 JUNB MCL1 MUC1 STAT3
13
Show member pathways
11.35 IL9 JAK3 STAT3
14
Show member pathways
11.29 CSF1R JAK3 STAT3
15 11.28 PAX5 PTPRC STAT3 TNFRSF8
16 11.26 JAK3 PTPRC STAT3
17 10.91 GZMB MCL1

GO Terms for Anaplastic Large Cell Lymphoma

Cellular components related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.36 CLU GZMB JAK3 MCL1 MUC1 NPM1

Biological processes related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.91 CLU GZMB MCL1 TNFSF8 TRAF1
2 negative regulation of apoptotic process GO:0043066 9.8 CSF1R MCL1 NPM1 STAT3
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.55 ALK CLU NPM1 TNFRSF8 TRAF1
4 response to cytokine GO:0034097 9.5 JUNB MCL1 STAT3
5 interleukin-15-mediated signaling pathway GO:0035723 9.48 JAK3 STAT3
6 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.46 JAK3 STAT3
7 regulation of B cell receptor signaling pathway GO:0050855 9.43 PAX5 PTPRC
8 cytokine-mediated signaling pathway GO:0019221 9.43 CSF1R JAK3 JUNB MCL1 MUC1 STAT3
9 regulation of JAK-STAT cascade GO:0046425 9.4 JAK3 PTPRC
10 interleukin-21-mediated signaling pathway GO:0038114 9.37 JAK3 STAT3
11 regulation of extrinsic apoptotic signaling pathway GO:2001236 9.26 PTPRC TRAF1
12 interleukin-9-mediated signaling pathway GO:0038113 8.8 IL9 JAK3 STAT3

Molecular functions related to Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.8 CSF1R JAK3 STAT3

Sources for Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....